{"id":411,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2014-06-19","marketCap":934.3543090820312,"name":"Ardelyx Inc","phone":"15107457047.0","outstanding":232.13999938964844,"symbol":"ARDX","website":"https://www.ardelyx.com/","industry":"Biotechnology"},"price":3.96875,"year":2023,"month":11,"day":3,"weekday":"Friday","title":"The Potential Impact of Energy Prices on Ardelyx Inc's Stock Performance","date":"2023-11-03","url":"/posts/2023/11/03/ARDX","content":[{"section":"Introduction","text":"Ardelyx Inc, a biopharmaceutical company, operates in the healthcare industry and focuses on the discovery, development, and commercialization of innovative medicines. While its primary focus is not directly related to energy, changes in energy prices and energy-related policies can still have an indirect impact on the company's stock performance."},{"section":"Energy Costs and Operational Expenses","text":"Like many businesses, Ardelyx Inc relies on energy resources to power its operations. Energy costs constitute a significant portion of the company's operational expenses. Fluctuations in energy prices can, therefore, influence its overall costs of production. When energy prices rise, it puts upward pressure on Ardelyx Inc's costs, potentially reducing profit margins. Conversely, a decrease in energy prices can lead to cost savings and improved profitability."},{"section":"Regulatory Environment","text":"Energy-related policies and regulations can also impact Ardelyx Inc's stock performance. Governments worldwide are increasingly focusing on promoting renewable energy and reducing carbon emissions. Policy changes that support renewable energy sources, such as solar or wind power, may lead to increased demand for products or services offered by companies operating in these sectors. While Ardelyx Inc may not be directly involved in renewable energy, the overall market sentiment towards clean energy can influence investor confidence in the stock. Positive developments in energy policies could potentially drive Ardelyx Inc's stock price higher."},{"section":"Supply Chain and Market Dynamics","text":"Changes in energy prices can have cascading effects on the broader market and the supply chain. Fluctuations in oil prices, for example, can impact transportation costs, affecting the delivery of raw materials and finished products. This chain reaction can influence the company's production timelines, inventory management, and overall business operations. Any disruptions caused by energy price volatility might create challenges for Ardelyx Inc, potentially impacting its stock performance."},{"section":"Investor Sentiment and Market Volatility","text":"Energy price instability can contribute to overall market volatility. Heightened uncertainty surrounding energy costs may increase investor nervousness and lead to more significant price fluctuations in the stock market. As an indirect consequence, these market dynamics can affect Ardelyx Inc's stock performance, with potential selloffs or buying opportunities emerging due to sentiment shifts. Close monitoring of energy price trends is crucial when analyzing the potential impact on Ardelyx Inc's stock."},{"section":"Conclusion","text":"While Ardelyx Inc's core business is in the healthcare industry, it is not immune to the influence of energy prices and energy-related policies. Changes in energy costs can impact the company's operational expenses and profitability. Additionally, energy-related regulations and market dynamics can indirectly affect investor sentiment and market volatility. Therefore, keeping a close eye on the energy sector and its potential impact on Ardelyx Inc is crucial for investors and stakeholders."}],"tags":["CrossUnder200","Short","Biotechnology"],"news":[{"category":"company","date":1698849733,"headline":"Ardelyx, Inc. (NASDAQ:ARDX) Q3 2023 Earnings Call Transcript","id":123566339,"image":"https://media.zenfs.com/en/insidermonkey.com/cf401c8db983235b966353ea102cc607","symbol":"ARDX","publisher":"Yahoo","summary":"Ardelyx, Inc. (NASDAQ:ARDX) Q3 2023 Earnings Call Transcript October 31, 2023 Ardelyx, Inc. beats earnings expectations. Reported EPS is $0.02909, expectations were $-0.11. Operator: Good day and welcome to the Ardelyx Third Quarter 2023 Earnings Conference Call. [Operator Instructions] Please note, this event is being recorded. I would now like to turn the conference over […]","url":"https://finance.yahoo.com/news/ardelyx-inc-nasdaq-ardx-q3-144213098.html"},{"category":"company","date":1698826920,"headline":"Wall Street Analysts Are Bullish on Top Healthcare Picks","id":123550642,"image":"","symbol":"ARDX","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3189035581"},{"category":"company","date":1698826320,"headline":"Ardelyx price target raised to $11 from $9 at H.C. Wainwright","id":123554353,"image":"","symbol":"ARDX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3189020286"},{"category":"company","date":1698816900,"headline":"Piper Sandler Keeps Their Buy Rating on Ardelyx (ARDX)","id":123554354,"image":"","symbol":"ARDX","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3188836899"},{"category":"company","date":1698808555,"headline":"Q3 2023 Ardelyx Inc Earnings Call","id":123566340,"image":"https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png","symbol":"ARDX","publisher":"Yahoo","summary":"Q3 2023 Ardelyx Inc Earnings Call","url":"https://finance.yahoo.com/news/q3-2023-ardelyx-inc-earnings-031555920.html"},{"category":"company","date":1698786540,"headline":"Why Ardelyx Stock Soared Today","id":123536592,"image":"https://s.yimg.com/ny/api/res/1.2/sIT2fsE9ebwR8Nt0zmsHiQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/d7d7b7af10b83de8105c430afc72933d","symbol":"ARDX","publisher":"Yahoo","summary":"Ardelyx delivered a strong quarter thanks to solid demand for its first FDA-approved product. Here's what investors need to know.","url":"https://finance.yahoo.com/m/68245b88-9436-34aa-9bf9-79d2a38a5c1d/why-ardelyx-stock-soared-today.html"},{"category":"company","date":1698759842,"headline":"Ardelyx (ARDX) Price Target Increased by 6.72% to 9.25","id":123520965,"image":"","symbol":"ARDX","publisher":"Fintel","summary":"","url":"https://fintel.io/news/ardelyx-ardx-price-target-increased-by-672-to-925-318"},{"category":"company","date":1698756007,"headline":"Ardelyx (ARDX) Q3 Earnings and Revenues Top Estimates","id":123527291,"image":"https://media.zenfs.com/en/zacks.com/1a018a29aef5adbf5b4319f32058e209","symbol":"ARDX","publisher":"Yahoo","summary":"Ardelyx (ARDX) delivered earnings and revenue surprises of 127.27% and 155.31%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?","url":"https://finance.yahoo.com/news/ardelyx-ardx-q3-earnings-revenues-124007509.html"},{"category":"company","date":1698755460,"headline":"Analysts’ Top Healthcare Picks: Ardelyx (ARDX), Argenx Se (ARGX)","id":123537782,"image":"","symbol":"ARDX","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3187359812"},{"category":"company","date":1698752532,"headline":"Ardelyx, Inc. (ARDX) Q3 2023 Earnings Call Transcript","id":123521641,"image":"https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png","symbol":"ARDX","publisher":"SeekingAlpha","summary":"Ardelyx, Inc. (NASDAQ:NASDAQ:ARDX) Q3 2023 Earnings Conference Call October 31, 2023 8:00 AM ETCompany ParticipantsCaitlin Lowie - Vice President of...","url":"https://seekingalpha.com/article/4645418-ardelyx-inc-ardx-q3-2023-earnings-call-transcript"},{"category":"company","date":1698750300,"headline":"Arista Networks, JinkoSolar, Repligen, Shutterstock And Other Big Stocks Moving Higher On Tuesday","id":123522419,"image":"","symbol":"ARDX","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3187220546"},{"category":"company","date":1698750000,"headline":"Ardelyx Reports Third Quarter 2023 Financial Results and Updates 2023 U.S. IBSRELA® Net Sales Revenue Guidance","id":123527292,"image":"https://s.yimg.com/ny/api/res/1.2/ghwkpWPFr6gtLnmMtiQ_EA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD0yNzY-/https://media.zenfs.com/en/globenewswire.com/a5aacbe5b6ed8684e6c7628685bbcf07","symbol":"ARDX","publisher":"Yahoo","summary":"Continued successful launch of IBSRELA, with Q3 net sales revenue of $22.3 million; Company currently expects 2023 full year IBSRELA U.S. net sales revenue to be $76 to $78 million XPHOZAH® launch underway following October 17, 2023 FDA approval Company ends Q3 with $165.1 million in cash, cash equivalents and short-term investments Conference call scheduled for 8:00 AM Eastern Time WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founde","url":"https://finance.yahoo.com/news/ardelyx-reports-third-quarter-2023-110000852.html"},{"category":"company","date":1698737340,"headline":"Ardelyx: Q3 Earnings Snapshot","id":123522421,"image":"","symbol":"ARDX","publisher":"Associated Press, The","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=w5ka7g1jl0"},{"category":"company","date":1698736800,"headline":"ARDX, HMST and RVPH are among pre market gainers","id":123522422,"image":"","symbol":"ARDX","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3186883709"},{"category":"company","date":1698734760,"headline":"","id":123522424,"image":"","symbol":"ARDX","publisher":"GuruFocus","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3186841849"},{"category":"company","date":1698734100,"headline":"Ardelyx GAAP EPS of $0.03 beats by $0.14, revenue of $56.4M beats by $33.83M","id":123522425,"image":"","symbol":"ARDX","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3186828555"},{"category":"company","date":1698732120,"headline":"Ardelyx reports Q3 EPS 3c, consensus (11c)","id":123522426,"image":"","symbol":"ARDX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3186792240"},{"category":"company","date":1698716100,"headline":"Ardelyx gains as Ibsrela drives strong Q3 beat","id":123554356,"image":"","symbol":"ARDX","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3187464160"},{"category":"company","date":1698702120,"headline":"Ardelyx, Inc. Reports Employment Inducement Grants","id":123508368,"image":"https://s.yimg.com/ny/api/res/1.2/ghwkpWPFr6gtLnmMtiQ_EA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD0yNzY-/https://media.zenfs.com/en/globenewswire.com/a5aacbe5b6ed8684e6c7628685bbcf07","symbol":"ARDX","publisher":"Yahoo","summary":"WALTHAM, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced between October 11, 2023 and October 29, 2023 the compensation committee of the company’s board of directors granted forty-seven new non-executive employees options to purchase an aggregate of 635,024 shares of the company’s common st","url":"https://finance.yahoo.com/news/ardelyx-inc-reports-employment-inducement-214200680.html"},{"category":"company","date":1698662353,"headline":"This Ardelyx Insider Increased Their Holding By 95% Last Year","id":123496157,"image":"https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305","symbol":"ARDX","publisher":"Yahoo","summary":"Looking at Ardelyx, Inc.'s ( NASDAQ:ARDX ) insider transactions over the last year, we can see that insiders were net...","url":"https://finance.yahoo.com/news/ardelyx-insider-increased-holding-95-103913914.html"},{"category":"company","date":1698662160,"headline":"Ardelyx Q3 2023 Earnings Preview","id":123510490,"image":"","symbol":"ARDX","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3185199801"},{"category":"company","date":1698660180,"headline":"Notable earnings before Tuesday's open","id":123496948,"image":"","symbol":"ARDX","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3185155513"},{"category":"company","date":1698570840,"headline":"3 Penny Stocks to Buy and Hold for the Next 10 Years","id":123483832,"image":"","symbol":"ARDX","publisher":"InvestorPlace","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3184051204"},{"category":"company","date":1698225960,"headline":"Jefferies biotechnology analyst to hold an analyst/industry conference call","id":123400588,"image":"","symbol":"ARDX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3177182461"},{"category":"company","date":1698062820,"headline":"Ardelyx Shares Positive Data on Symptom Response During Treatment With IBSRELA® (tenapanor) for IBS-C and hosts IBS-C Product Theater at ACG 2023","id":123334774,"image":"https://s.yimg.com/ny/api/res/1.2/ghwkpWPFr6gtLnmMtiQ_EA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD0yNzY-/https://media.zenfs.com/en/globenewswire.com/a5aacbe5b6ed8684e6c7628685bbcf07","symbol":"ARDX","publisher":"Yahoo","summary":"WALTHAM, Mass., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, announced that they will share positive data on IBSRELA® (tenapanor) via an oral presentation and two posters at the American College of Gastroenterology (ACG) annual meeting, being held October 20 to 25 in Vancouver, Canada. IBSRELA, discovered and","url":"https://finance.yahoo.com/news/ardelyx-shares-positive-data-symptom-120700924.html"},{"category":"company","date":1698046140,"headline":"Ardelyx shares data on IBSRELA via oral presentation, posters","id":123342170,"image":"","symbol":"ARDX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3173240279"},{"category":"company","date":1697796660,"headline":"First Week of December 15th Options Trading For Ardelyx (ARDX)","id":123287082,"image":"","symbol":"ARDX","publisher":"Stock Options Channel","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3169973012"},{"category":"company","date":1697796240,"headline":"Biotech Alert: Searches spiking for these stocks today","id":123285328,"image":"","symbol":"ARDX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3169965850"}]}